Neurogene (NASDAQ:NGNE – Get Free Report) and Connect Biopharma (NASDAQ:CNTB – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.
Profitability
This table compares Neurogene and Connect Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neurogene | N/A | -45.10% | -41.00% |
| Connect Biopharma | N/A | -165.41% | -121.58% |
Volatility and Risk
Neurogene has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.23, meaning that its stock price is 123% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neurogene | 1 | 0 | 4 | 1 | 2.83 |
| Connect Biopharma | 1 | 0 | 7 | 0 | 2.75 |
Neurogene presently has a consensus price target of $83.67, indicating a potential upside of 193.77%. Connect Biopharma has a consensus price target of $6.86, indicating a potential upside of 534.92%. Given Connect Biopharma’s higher probable upside, analysts plainly believe Connect Biopharma is more favorable than Neurogene.
Valuation and Earnings
This table compares Neurogene and Connect Biopharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neurogene | $930,000.00 | 612.78 | -$90.35 million | ($5.03) | -5.66 |
| Connect Biopharma | $60,000.00 | 1,133.46 | -$55.48 million | ($1.19) | -0.91 |
Connect Biopharma has lower revenue, but higher earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
52.4% of Neurogene shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 11.7% of Neurogene shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Connect Biopharma beats Neurogene on 8 of the 14 factors compared between the two stocks.
About Neurogene
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.
